| Abstract |
Treatment of head and neck cancer with cisplatin-based combination
chemotherapy has yielded increased complete response rates. In spite of
the initial good response, recurrent cancer after chemotherapy does not
respond to cisplatin based chemotherapy. In recent years, the analogues of
taxol have used in a new chemotherapy treatments for head and neck cancer.
The purpose of this study was to develop the acquired resistance to
cisplatin in head and neck cancer cell line and to study the cross-
resistance of docetaxel and 5-fluorouracil (5-FU) as compared to the
parental cells in vitro.
Two different human head and neck cancer cell lines (PNUH-12, SNU-899)
were studied. We developed two cisplatin resistant cell lines (PNUH-12 R1,
SNU-899 R1) by exposing them to near continuous increasing concentration
of cisplatin. The morphology, growth curve of resistant cell lines were
studied and the resistance of these cell lines to the cisplatin, docetaxel
and 5-FU were compared to that of parental cells by MTT assay.
The pattern of growth and shape of PNUH-12 R1 and SNU 899 R1 cell lines
showed similarity to their parent cell lines. The growth curve of these
cell lines were suppressed when compared with the parental cells. When
compared to the parental cells, PNUH-12 R1 cells were 2.0-fold, 3.8-fold,
and 1.4-fold resistant, and SNU 899 R1 cells 3.5-fold, 6.7-fold, and 15.0-
fold resistant to cisplatin, docetaxel and 5-FU, respectively.
In our study, cisplatin resistant cell lines of head and neck cancer have
strong cross-resistance to docetaxel. However, there was difference in
cross-resistance to 5-FU between these cell lines.
|
|---|
